Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Treatment of lipid disorders in obesity.

Tonstad S, Després JP.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):1069-80. doi: 10.1586/erc.11.83. Review.

PMID:
21878051
2.

Obesity and dyslipidemia.

Repas T.

S D Med. 2011 Jul;64(7):241-3, 245, 247 passim.

PMID:
21848021
3.
4.
5.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
6.

The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.

Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA.

Rev Cardiovasc Med. 2008 Fall;9(4):239-58. Review.

PMID:
19122582
7.

Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.

Chan DC, Barrett HP, Watts GF.

Am J Cardiovasc Drugs. 2004;4(4):227-46. Review.

PMID:
15285698
8.

Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.

Nakajima K.

Curr Clin Pharmacol. 2010 May;5(2):133-9. Review.

PMID:
20156152
9.

[Lipid management--treatment goal and strategy].

Koshiyama H.

Nihon Rinsho. 2006 Nov;64(11):2102-6. Review. Japanese.

PMID:
17087303
10.

[Update dyslipidemia].

Parhofer KG.

Internist (Berl). 2013 Sep;54(9):1089-103. doi: 10.1007/s00108-013-3335-3. German.

PMID:
23928724
11.

[Diabetic dyslipoproteinemia: beyond LDL].

Merkel M.

Dtsch Med Wochenschr. 2009 May;134(20):1067-73. doi: 10.1055/s-0029-1222571. Epub 2009 May 6. Review. German.

PMID:
19421932
12.

Lipid nephrotoxicity: new concept for an old disease.

Gyebi L, Soltani Z, Reisin E.

Curr Hypertens Rep. 2012 Apr;14(2):177-81. doi: 10.1007/s11906-012-0250-2. Review.

PMID:
22290079
13.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

14.

[The fixed combination of pravastatin and fenofibrate: what can it provide?].

Díaz Rodríguez Á.

Clin Investig Arterioscler. 2014 Jul;26 Suppl 1:12-6. doi: 10.1016/S0214-9168(14)70020-8. Spanish.

PMID:
25043541
15.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

16.

Management of dyslipidemia in the metabolic syndrome.

Tan KC.

Cardiovasc Hematol Disord Drug Targets. 2007 Jun;7(2):99-108. Review.

PMID:
17584044
17.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
18.

[Treatment of dyslipidemia: how and when to combine lipid lowering drugs].

Schulz I.

Arq Bras Endocrinol Metabol. 2006 Apr;50(2):344-59. Epub 2006 May 23. Review. Portuguese.

19.

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

Rizzo M, Berneis K, Carmina E, Rini GB.

Am J Obstet Gynecol. 2008 Jan;198(1):28.e1-5. doi: 10.1016/j.ajog.2007.09.014. Review.

PMID:
18166299
20.
Items per page

Supplemental Content

Write to the Help Desk